2017 Press Releases


Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/30/17Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
HOUSTON, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will present at three upcoming healthcare investor conferences. Conference Details: Event: 2017 Wells Fargo Securities Healthcare Conference Date/Time: Wednesday, September 6 at 3:00 p.m. EDT Location: Boston, MA Event: Ladenburg Thalmann 2017 ... 
Printer Friendly Version
08/08/17Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Company updates BPX-501 program Enrollment progressing in early clinical trials of CAR T and TCR product candidates Company to host conference call and webcast on August 8 at 5:00 PM EDT HOUSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the second quarter ended June 30, 2017, and provided an updat... 
Printer Friendly Version
08/03/17Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer
HOUSTON, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Gregory Naeve, Ph.D., has been appointed as Chief Business Officer, effective August 21. Dr. Naeve, who will report to CEO Rick Fair, will lead product and portfolio strategy as well as business development for the Company. ... 
Printer Friendly Version
08/01/17Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017
HOUSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday, August 8, 2017 at 5:00 PM EDT to report its second quarter 2017 financial results and provide a corporate update. To access the call, participants should dial 877-407-3103 (U.S. domestic) and 201-49... 
Printer Friendly Version
06/23/17Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
Oral presentation highlights high success rate of haploidentical transplants, with low incidence of disease relapse and uncontrolled GvHD MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced data from its ongoing multicenter BP-004 trial of BPX-501 and rimiducid in a cohort of pediatric patients with acute leukemias who... 
Printer Friendly Version
06/23/17Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
U.S. and E.U. data suggest favorable outcomes to alternative transplants in patients with hematologic cancers and genetic blood diseases MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, announced that results will be presented today from its global BP-004 clinical trial of BPX-501 in the Presidential Symposium at the 22nd Congress ... 
Printer Friendly Version
05/31/17Bellicum Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
HOUSTON, May 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY. A live webcast of the presentation may be accessed from the News & Events section o... 
Printer Friendly Version
05/18/17Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association
Overall-cohort abstract on BPX-501 selected for presentation at Presidential Symposium Oral and poster presentations highlight BPX-501 data in leukemias and hemoglobinopathies HOUSTON, May 18, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that three abstracts have been accepted for presentation at the 22nd Congress of the European He... 
Printer Friendly Version
05/15/17Bellicum Pharmaceuticals Announces Management Changes
HOUSTON, May 15, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Annemarie Moseley, Ph.D., M.D., the Company’s Chief Operating Officer and Executive Vice President of Clinical Development, has announced her intention to leave the organization, effective July 31, 2017. Dr. Moseley will transition her responsibilities over this period a... 
Printer Friendly Version
05/08/17Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results
HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent developments. “We had a productive first quarter across our pipeline,” said Rick Fair, Bellicum’s President & Chief Executive Officer. “We continued to make progress on the reg... 
Printer Friendly Version
04/26/17Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
HOUSTON, April 26, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3 at 2:10 p.m. EDT in Boston, Massachusetts. A live webcast of the presentation may be accessed from the News & E... 
Printer Friendly Version
04/04/17Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR
HOUSTON, April 04, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced two presentations of preclinical results on the Company’s proprietary dual-switch technology for use in CAR-T and TCR product candidates at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. “We’re excited to report compelling pre... 
Printer Friendly Version
03/30/17Bellicum Pharmaceuticals Announces Closing of Public Offering
HOUSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $12.00 per share. The aggregate offering size was approximately $69.0 million, before deducting the underwriting... 
Printer Friendly Version
03/23/17Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HOUSTON, March 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. The aggregate offering size, before deducting the underwriting discounts and commissions and other offering expenses, is expected to be approximately $60.0 million. The offering is expected to close on or about March 29, 2017, subject to customary closing cond... 
Printer Friendly Version
03/22/17Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOUSTON, March 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering will be offered by Bell... 
Printer Friendly Version
03/13/17Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
On track to complete enrollment in E.U. registration trials for BPX-501 and rimiducid this year Reported updated clinical data with BPX-501 demonstrating rapid immune recovery and low rates of GvHD in children with blood cancers and orphan inherited blood disorders Initiated clinical trials of controllable CAR T and TCR product candidates  Management to host conference call and webcast today at 5 p.m. Eastern HOUSTON, March 13, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nas... 
Printer Friendly Version
03/08/17Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference
HOUSTON, March 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Barclays Global Healthcare Conference on Wednesday, March 15 at 4:20 p.m. EDT in Miami, FL. A live webcast of the presentation may be accessed from the News & Events section of the... 
Printer Friendly Version
03/06/17Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017
HOUSTON, March 06, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Monday, March 13, 2017 at 5:00 p.m. Eastern to report its fourth quarter and full year 2016 financial results and provide a corporate update. To access the call, participants should dial 877-407-3103 (U.S. ... 
Printer Friendly Version
02/22/17Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers
Study demonstrates consistent, durable outcomes at six and 12 months with very low incidence of GvHD HOUSTON, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation of updated clinical results from its multicenter BP-004 clinical trial of BPX-501 and rimiducid at the 2017 BMT Tandem Meetings. Results on 73 patients with... 
Printer Friendly Version
02/21/17Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate
BPX-601 being studied in pancreatic cancers expressing PSCA HOUSTON, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has dosed the first patient with BPX-601, the first CAR T-cell product candidate to enter clinical studies that is designed to enable control over the expansion and stimulation of the cells. BPX-601 targets soli... 
Printer Friendly Version
01/31/17Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
HOUSTON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Rick Fair as President and Chief Executive Officer, and as a member of the Board of Directors, effective immediately. Mr. Fair joins Bellicum from Genentech/Roche, where he was Senior Vice President, Head of Onco... 
Printer Friendly Version